KDC-MN-129 – Kodiac biolabs

Plain-language summaryIntrigue 45 / 100

Thymogen is a synthetic dipeptide (Glu-Trp) immunomodulator developed in Russia, derived from research on thymic hormones. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundSingle-lab provenance

37/100

Russian-approved thymic dipeptide with real but geographically isolated evidence and conventional immunomodulatory mechanism

Thymogen is the synthetic Glu-Trp dipeptide, pulled from bovine thymus extract by the fractionation work that produced the broader thymalin literature. It’s a legitimately interesting research object in a narrow sense: two amino acids, modest immunomodulatory activity, and a regulatory approval history that puts it above the purely speculative tier. But we have to be honest about what we’re dealing with here.

The mechanism story is straightforward and not especially exciting. Thymic peptides generally modulate T-cell maturation and cytokine output, and Thymogen does this at the dipeptide level. Thats useful to know, but the actual pharmacology is conventional thymic biology, not a novel axis. Compare it to thymosin alpha-1, which has a much richer literature, phase 2/3 trial experience in HIV and hepatitis, and real credibility in the immunostimulant space. Against that competition, Thymogen is clearly secondary.

The evidence situation is the main drag. The literature is almost entirely Russian-language, produced within a small set of institutes associated with the Khavinson/bioregulator tradition. Regulatory approval in Russia and several former Soviet states means there’s real clinical use, but the methodology behind those approvals is opaque by Western standards. There’s essentially no independent multi-lab replication, no phase 2/3 data by EMA or FDA standards, and no published systematic reviews we can assess with confidence.

What we like: the synthetic dipeptide approach is clean. If someone wants to study minimal thymic signaling molecules as probes for T-cell maturation pathways, Thymogen is small, well-defined, and accessible. That’s genuinely more useful than starting with a crude thymus extract. And the intranasal route is interesting from a delivery standpoint if you’re studying mucosal immune signaling in rodent models.

What we don’t like: the mechanism doesn’t differentiate it from better-studied alternatives in the thymic peptide space. Thymosin alpha-1 exists. Thymopentin exists. The Glu-Trp story hasn’t generated the kind of mechanism-deep papers that would justify prioritizing this over those options for a serious research program. The approved-in-Russia status is worth noting but doesn’t substitute for replication outside that regulatory tradition.

For investigators specifically building out a thymic peptide panel or studying minimal bioactive dipeptides as a structural class, Thymogen has real bench value. For most Western research contexts, the evidence base doesn’t justify leading with it over better-characterized alternatives.

Novelty: 48
Mechanism promise: 33
In-category differentiation: 28
Evidence quality: 37
Translational signal: 42
Research bench value: 30

Rationale Thymogen has regulatory approval within Russia and the FSU but the evidence base is single-consortium and lacks Western replication; mechanism is conventional thymic immunobiology with no novel axis, and thymosin alpha-1 clearly dominates the therapeutic space it occupies.

Synthetic dipeptide immunomodulator

A synthetic dipeptide (Glu-Trp) developed in Russia as an immunomodulator for infectious and post-surgical immune support.

Abstract

Thymogen is the dipeptide L-glutamyl-L-tryptophan, developed in Russia at the Institute of Bioregulation and Gerontology. The compound was identified through fractionation of thymalin (bovine thymus extract) as one of the active components. Thymogen is approved in Russia and several former Soviet states for infectious diseases, post-surgical immune support, and hematopoietic recovery after chemotherapy. Mechanism includes modest T-cell maturation effects and cytokine modulation. Administered intranasally or intramuscularly. Doses are 100 micrograms per day in 3 to 10 day courses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-129Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-129

Thymogen

Abstract

Read the full monograph